Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals

Comparing the hematotoxicity in patients that were treated with locally manufactured <sup>177</sup>Lu-HA-DOTATATE with patients that were treated with Lutathera<sup>®</sup> and assessing different treatment intervals in both groups (8 vs. 11 weeks), revealed that there is overall a low to moderate incidence of significant changes in hematological and renal parameters directly after PRRT. Recovery trends of hematological and renal parameters after 1 year suggest that patients treated with locally manufactured <sup>177</sup>Lu-HA-DOTATATE might benefit from a longer treatment interval of 11 weeks regarding their PLT counts. Given the risk of developing hematological diseases such as therapy-related myeloid neoplasms years after PRRT, longer observational periods after PRRT will be crucial.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-04-24
DOI
https://doi.org/10.3390/cancers17091423
Citations
2
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
2.71
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals

Lena M. Unterrainer, Harun Ilhan, Christoph Josef Auernhammer, Johannes Rübenthaler et al.
2 citations
Cancers
Neuroendocrine Tumor Research Advances
2.71
article

Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals

Lena M. Unterrainer, Harun Ilhan, Christoph Josef Auernhammer, Johannes Rübenthaler, Markus Hofmann, Johannes Toms, Adrien Holzgreve, Marcus Unterrainer, Christine Spitzweg, Leonie Beyer, Astrid Delker, Mathias J. Zacherl, Sophie C. Kunte, F.J. Gildehaus
article en
2 citations

Abstract

Comparing the hematotoxicity in patients that were treated with locally manufactured <sup>177</sup>Lu-HA-DOTATATE with patients that were treated with Lutathera<sup>®</sup> and assessing different treatment intervals in both groups (8 vs. 11 weeks), revealed that there is overall a low to moderate incidence of significant changes in hematological and renal parameters directly after PRRT. Recovery trends of hematological and renal parameters after 1 year suggest that patients treated with locally manufactured <sup>177</sup>Lu-HA-DOTATATE might benefit from a longer treatment interval of 11 weeks regarding their PLT counts. Given the risk of developing hematological diseases such as therapy-related myeloid neoplasms years after PRRT, longer observational periods after PRRT will be crucial.

CancersVol. 17(9)
University of California, Los Angeles (US), LMU Klinikum (DE), European Neuroendocrine Tumor Society (DE), Ihre-Radiologen (DE), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Openalex Percentile: Top 11%
Neuroendocrine Tumor Research Advances
2.71
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.